US advisers endorse PCSK9 Praluent, but limited population
This article was originally published in Scrip
Executive Summary
Not wanting to withhold a new type of cholesterol-lowering drug for two years from desperate patients while waiting for cardiovascular outcomes trial (CVOT) data, a panel of experts on 9 June supported Sanofi and Regeneron Pharmaceuticals putting their proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Praluent (alirocumab) on the US market, despite fears that an FDA approval could mean the large study testing the medicine's ability to prevent heart attacks may be abandoned.
You may also be interested in...
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.
Phase III Boost For Esperion But Does It Own Its Destiny?
Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.